StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Selling, general and administrative expenses by Quarter

Selling, general and administrative (SG&A) expenses — Total ($M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Selling, general and administrative expenses: $582M in Q2 2026, up 37.1% from a year earlier. That is the highest of the 70 quarters on record here.

Latest, Q2 2026
582
Period ended Jun 30, 2026
Change on a year earlier
+37.1%
425 in Q2 2025
History
70 quarters
Since Q1 2009
Sources
41
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Consolidated Statements of Operations & Segment Note.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSelling, general and administrative (SG&A) expenses — Total ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026582+37.1%Form 10-Q (filed 2026-08-04) ↗
Q1 2026Mar 31, 2026494+24.5%Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 2025487+29.0%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025445+19.7%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 2025425+14.1%Form 10-Q (filed 2026-08-04) ↗
Q1 2025Mar 31, 2025396+15.7%Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 2024378+2.3%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024372+40.9%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 2024372+41.7%Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 2024343+42.1%Form 10-Q (filed 2025-05-06) ↗
Q4 2023Dec 31, 2023369+38.0%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 2023264+6.9%Form 10-Q (filed 2024-11-05) ↗
Q2 2023Jun 30, 2023263+22.0%Form 10-Q (filed 2024-08-02) ↗
Q1 2023Mar 31, 2023241+12.0%Form 10-Q (filed 2024-05-07) ↗
Q4 2022Dec 31, 2022267+4.8%Form 10-K (filed 2025-02-13) ↗
Q3 2022Sep 30, 2022247+24.5%Form 10-Q (filed 2023-11-07) ↗

Breakdown

What makes up selling, general and administrative expenses

Cite this data

StockData. (2026). Vertex Pharmaceuticals Selling, general and administrative expenses ($M), quarterly Q1 2009–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/seg-sga-tot

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.